Clinical and molecular biomarkers predicting response to PARP inhibitors in ovarian cancer.

ABSTRACT:

Objective

To determine the useful biomarker for predicting the effects of poly-(ADP ribose)-polymerase (PARP) inhibitors in Japanese patients with ovarian cancer.

Methods

We collected clinical information and performed molecular biological analysis on 42 patients with ovarian, fallopian tube, and primary peritoneal carcinomas who received PARP inhibitors.

Results

Among the analyzed patients with ovarian cancer, 23.8% had germline BRCA mutation (gBRCAm), 42.9% had homologous recombination repair-related gene mutation (HRRm), and 61.1% had a genomic instability score (GIS) of ≥42. Patients with HRRm had a significantly longer progression-free survival (PFS) than those without HRRm (median PFS 35.6 vs. 7.9 months; p=0.009), with a particularly marked increa

SUBMITTER: Nozaki T 

PROVIDER: S-EPMC11262903 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature